Search hospitals > Ohio > Columbus
Riverside Methodist Hospital
Claim this profileColumbus, Ohio 43214
Global Leader in Parotid Gland Cancer
Global Leader in Relapse
Conducts research for Cervical Adenocarcinoma
Conducts research for Ovarian Cancer
Conducts research for Breast Cancer
389 reported clinical trials
30 medical researchers
Summary
Riverside Methodist Hospital is a medical facility located in Columbus, Ohio. This center is recognized for care of Parotid Gland Cancer, Relapse, Cervical Adenocarcinoma, Ovarian Cancer, Breast Cancer and other specialties. Riverside Methodist Hospital is involved with conducting 389 clinical trials across 712 conditions. There are 30 research doctors associated with this hospital, such as Timothy D. Moore, Steven Yakubov, MD, Aine E. Clements, and Carlos Sanchez, MD.Area of expertise
1Parotid Gland Cancer
Global LeaderStage IV
Stage III
Stage II
2Relapse
Global LeaderStage IV
Stage III
Stage I
Top PIs
Timothy D. MooreThe Mark H Zangmeister Center6 years of reported clinical research
Expert in Parotid Gland Cancer
Expert in Lung Cancer
126 reported clinical trials
208 drugs studied
Steven Yakubov, MDOhio Health Research Institute6 years of reported clinical research
Studies Congenital Aortic Stenosis
Studies Mitral Regurgitation
8 reported clinical trials
14 drugs studied
Aine E. ClementsOhioHealth Mansfield Hospital2 years of reported clinical research
Studies Endometrial Carcinoma
Studies Ovarian Cancer
7 reported clinical trials
32 drugs studied
Carlos Sanchez, MDOhioHealth Research Institute6 years of reported clinical research
Studies Mitral Regurgitation
Studies Stroke
6 reported clinical trials
10 drugs studied
Clinical Trials running at Riverside Methodist Hospital
Breast Cancer
Lung Cancer
Ovarian Cancer
Cancer
Multiple Myeloma
Breast cancer
Parotid Gland Cancer
Non-Small Cell Lung Cancer
Pancreatic Cancer
Endometrial Cancer
Sacituzumab Govitecan + Pembrolizumab
for Triple Negative Breast Cancer
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.
Recruiting2 awards Phase 36 criteria
Radiation Therapy
for Brain Metastasis
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.
Recruiting2 awards Phase 312 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Riverside Methodist Hospital?
Where is Riverside Methodist Hospital located?
Who should I call to ask about financial aid or insurance network?
What insurance does Riverside Methodist Hospital accept?
What awards or recognition has Riverside Methodist Hospital received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.